This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Biovail plans third phase III PDP trial with 40 mg dose 2009-10-06 08:05 ET - News Release Mr. Bill Wells reports BIOVAIL PROVIDES UPDATE ON PIMAVANSERIN COLLABORATIVE DEVELOPMENT PROGRAM
Biovail Corp. has provided an update on its
phase III program with pimavanserin for Parkinson's disease psychosis
(PDP), which is being pursued in collaboration with Acadia
Pharmaceuticals Inc. Following the announcement in Stockwatch news on Sept. 1
of disappointing top-line results from the first phase III PDP trial,
Biovail and Acadia remain committed to the successful development of
pimavanserin and have established a development strategy that they
believe will strengthen the PDP program. The parties also intend to
pursue adjunctive therapy with pimavanserin for schizophrenia as a third
indication in the collaboration.
"We remain enthusiastic about pimavanserin's prospects in a number of
specialty CNS indications, including schizophrenia, where existing data
for the molecule as co-therapy are compelling," said Bill Wells,
Biovail's chief executive officer. "The steps we're taking today are
designed to fully exploit pimavanserin's potential and to bring this
novel therapeutic to market as quickly as possible."
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page